Medicare Pressed To Expand Home Infusion Emergency Access Plan Even Further
Executive Summary
Plan to allow broader coverage for home infused drugs during the COVID-19 emergency prompts opposition from providers seeking an approach more in line with commercial insurance practices.
You may also be interested in...
Future US Purchases Of Lilly’s Bamlanivimab Will Depend On Success Of Outpatient Infusion Process
HHS reverses course on cost sharing for the antibody and says patients will not have to pay. Operation Warp Speed will watch ‘extremely carefully’ to see if the health care system is able to adapt its practices to safely administer to the drug for COVID-19, officials say at a media briefing. FDA-authorized dose of the drug is not too low, Woodcock says.
Medicare Urged To Allow Home Infusion Plan With Direct Buying, Billing By Outside Providers
Manufacturers seek additional flexibility from Medicare to facilitate home infusions as surveys indicate patient visits to physician offices have dropped by 40% to 68% in recent weeks, signaling a decline in adherence for physician-administered drugs.
Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.